Yue Dai Selected Research

Peroxisome Proliferator-Activated Receptors (PPAR)

1/2022	Morin inhibits the transformation of fibroblasts towards myofibroblasts through regulating "PPAR-γ-glutaminolysis-DEPTOR" pathway in pulmonary fibrosis.
1/2018	Orally administered berberine ameliorates bleomycin-induced pulmonary fibrosis in mice through promoting activation of PPAR-γ and subsequent expression of HGF in colons.
4/2016	Madecassoside ameliorates bleomycin-induced pulmonary fibrosis in mice through promoting the generation of hepatocyte growth factor via PPAR-γ in colon.
1/2013	Asiatic acid isolated from Centella asiatica inhibits TGF-β1-induced collagen expression in human keloid fibroblasts via PPAR-γ activation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yue Dai Research Topics

Disease

33	Arthritis (Polyarthritis) 02/2024 - 05/2007
29	Experimental Arthritis 04/2024 - 04/2009
26	Colitis 01/2024 - 12/2014
25	Neoplasms (Cancer) 01/2024 - 04/2008
24	Inflammation (Inflammations) 09/2023 - 09/2002
23	Rheumatoid Arthritis 02/2024 - 05/2007
9	Hypertension (High Blood Pressure) 04/2024 - 07/2010
9	Fibrosis (Cirrhosis) 01/2023 - 06/2013
9	Body Weight (Weight, Body) 03/2015 - 05/2007
8	Pulmonary Fibrosis (Fibrosing Alveolitis) 11/2022 - 10/2013
7	Ulcerative Colitis 01/2024 - 12/2015
7	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 12/2022 - 08/2015
7	Hypersensitivity (Allergy) 01/2018 - 03/2004
6	Infections 01/2021 - 12/2014
5	Obesity 03/2024 - 08/2010
5	Hypoxia (Hypoxemia) 03/2023 - 04/2016
4	Atherosclerosis 03/2024 - 01/2021
4	Cardiovascular Diseases (Cardiovascular Disease) 09/2023 - 09/2018
4	Ureteral Obstruction 01/2023 - 06/2013
4	Wounds and Injuries (Trauma) 10/2022 - 06/2008
4	Keloid 08/2017 - 08/2012
4	Cicatrix (Scar) 11/2013 - 11/2008
4	Sepsis (Septicemia) 07/2012 - 02/2009
3	Abdominal Obesity 03/2024 - 01/2013
3	Neoplasm Metastasis (Metastasis) 01/2023 - 04/2016
3	Colitis-Associated Neoplasms 10/2022 - 10/2020
3	Asthma (Bronchial Asthma) 04/2022 - 01/2012
3	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 01/2017
3	Stroke (Strokes) 01/2021 - 03/2019
3	Weight Gain 01/2018 - 08/2010
3	Hepatocellular Carcinoma (Hepatoma) 07/2015 - 11/2011
3	Edema (Dropsy) 10/2013 - 09/2002
3	Overweight 03/2013 - 08/2010
3	Anaphylaxis (Anaphylactic Shock) 01/2005 - 09/2002
2	Malaria 05/2024 - 09/2023
2	Dyslipidemias (Dyslipidemia) 03/2024 - 01/2022
2	Type 2 Diabetes Mellitus (MODY) 03/2024 - 09/2015
2	Pathologic Constriction (Stenosis) 03/2024 - 01/2021

Drug/Important Bio-Agent (IBA)

16	norisoboldineIBA 04/2024 - 08/2012
15	Dextran SulfateIBA 10/2023 - 12/2014
13	AlkaloidsIBA 01/2022 - 05/2007
11	madecassosideIBA 12/2020 - 06/2008
10	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA 07/2023 - 01/2015
9	Proteins (Proteins, Gene)FDA Link 05/2024 - 06/2009
9	TriterpenesIBA 12/2023 - 06/2008
9	CollagenIBA 10/2019 - 05/2007
8	arctigeninIBA 01/2024 - 12/2014
8	CytokinesIBA 01/2024 - 04/2008
8	Interleukin-6 (Interleukin 6)IBA 01/2021 - 08/2012
8	SaponinsIBA 03/2015 - 05/2006
7	Fatty Acids (Saturated Fatty Acids)IBA 01/2023 - 10/2020
7	Therapeutic UsesIBA 01/2023 - 04/2010
7	tetrandrineIBA 01/2022 - 11/2015
6	Interleukin-17 (Interleukin 17)IBA 04/2022 - 05/2015
6	Bleomycin (Blenoxane)FDA LinkGeneric 01/2022 - 10/2013
6	AntigensIBA 01/2021 - 07/2003
5	Messenger RNA (mRNA)IBA 03/2024 - 06/2009
5	LipopolysaccharidesIBA 02/2024 - 10/2011
5	morinIBA 01/2023 - 12/2015
5	InflammasomesIBA 01/2023 - 01/2018
5	sinomenineIBA 10/2022 - 05/2015
5	madecassic acidIBA 01/2022 - 12/2014
5	isoquinolineIBA 12/2021 - 03/2013
5	2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amideIBA 01/2021 - 01/2018
5	ScopoletinIBA 07/2015 - 08/2010
4	bergeninIBA 05/2024 - 01/2017
4	FlavonoidsIBA 12/2022 - 01/2005
4	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2022 - 01/2013
4	Antihypertensive Agents (Antihypertensives)IBA 01/2020 - 03/2014
4	Interleukin-10 (Interleukin 10)IBA 01/2017 - 03/2015
4	peoniflorinIBA 06/2016 - 10/2011
4	coumarinIBA 12/2013 - 07/2009
4	Histamine (Histamine Dihydrochloride)FDA Link 05/2013 - 09/2002
4	Sodium Glutamate (Accent)IBA 03/2013 - 08/2010
4	p-Methoxy-N-methylphenethylamineIBA 01/2005 - 09/2002
3	Dextrans (Dextran)FDA Link 01/2024 - 01/2021
3	Mechanistic Target of Rapamycin Complex 1IBA 08/2023 - 08/2015
3	LigandsIBA 12/2022 - 01/2016
3	Triglycerides (Triacylglycerol)IBA 11/2022 - 12/2014
3	GlycosidesIBA 11/2022 - 02/2011
3	Butyrates (Butyrate)IBA 11/2022 - 11/2019
3	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 11/2022 - 04/2016
3	EnzymesIBA 04/2022 - 01/2022
3	CurcuminIBA 03/2021 - 05/2015
3	Uric Acid (Urate)IBA 01/2021 - 08/2010
3	LipidsIBA 01/2021 - 12/2014
3	Leucine (L-Leucine)FDA Link 01/2020 - 08/2015
3	BerberineIBA 11/2019 - 01/2017
3	Peroxidase (Myeloperoxidase)IBA 01/2018 - 10/2009
3	Collagen Type II (Type II Collagen)IBA 12/2015 - 05/2007
3	Phosphotransferases (Kinase)IBA 01/2015 - 08/2012
2	artemisinin (artemisinine)IBA 05/2024 - 09/2023
2	Apolipoproteins E (ApoE)IBA 03/2024 - 07/2021
2	IronIBA 02/2024 - 07/2008

Therapy/Procedure

17	Oral Administration 11/2023 - 06/2008
15	Therapeutics 05/2024 - 08/2012
10	Chinese Traditional Medicine (Traditional Chinese Medicine) 02/2024 - 07/2009
3	Intraperitoneal Injections 07/2022 - 01/2011
3	Ligation 02/2011 - 02/2009
3	Punctures 02/2011 - 02/2009